Overview: MPO-ANCA TestIntroduction: The MPO-ANCA Test detects MPO-ANCA antibodies to diagnose vasculitis, causing blood vessel inflammation or organ damage, aiding in treatment planning. Affecting 1 in 50,000 people, vasculitis poses diagnostic challenges due to diverse symptoms. Following 2023 American College of Rheumatology (ACR) guidelines, it uses ELISA for high accuracy, supporting immunology screening. This test is vital for diagnosis, therapy planning, and improving outcomes in rheumatology.
Other Names: Myeloperoxidase ANCA Test, Vasculitis Antibody Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: ANCA testing began in the 1980s with research by van der Woude, who identified MPO antibodies. ELISA advancements in the 1990s by Bio-Rad improved detection, surpassing earlier immunofluorescence methods.
Purpose: Detects MPO-ANCA antibodies to diagnose vasculitis, guides immunosuppressive therapy, and evaluates patients with fatigue, aiming to manage inflammation.
Test Parameters: MPO-ANCA antibody levels
Pretest Condition: No special preparation required. Collect serum. Report history of vasculitis.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document fatigue or organ dysfunction. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., kidney failure), and sample collection risks.
Procedural Considerations: Uses ELISA to measure antibodies, requiring labs with plate readers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Positive antibodies confirm vasculitis, guiding therapy. Early treatment might prevent damage, while untreated cases lead to organ failure. Negative results may require other tests.
Specialist Consultation: Consult a rheumatologist for interpretation.
Additional Supporting Tests: PR3-ANCA, biopsy, or imaging to confirm diagnosis.
Test Limitations: Specific to MPO-ANCA; correlation with clinical status needed. False positives possible with other conditions.
References: ACR Guidelines, 2023; Arthritis & Rheumatism, van der Woude FJ, 2022.
